TABLE 1.

Patient Characteristics

Patient no.	Age (y)	Type	Grade	Receptor status	Systemic therapy	Interval from last cycle to PET (d)
1	56	Ductal	2	HR+, HER2+	AC T H^*	15
2	51	Ductal	2	HR+, HER2+	EC T H	15
3	51	Ductal	1	HR+, HER2+	EC T H	6
4	35	Ductal	3	TNBC	EC T Cb	10
5	46	Ductal	3	HR+, HER2−	EC T	6
6	58	Ductal	3	HR−, HER2+	EC T H	0
7	56	Lobular	2	HR+, HER2+	EC T H	29
8	43	Ductal	2	TNBC	T Cb	15
9	38	Ductal	2	HR−, HER2+	EC T H	1
10	36	Lobular	2	HR+, HER2−	EC T	20
11	59	Ductal	2	HR+, HER2−	EC T	14
12	48	Ductal	3	HR−, HER2+	EC T H	15
13	34	Ductal	2	HR+, HER2-	EC T	8

↵* Additional investigational drug.
HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer; AC = doxorubicin; T = taxane; H = HER2-antibodies; EC = epirubicin; Cb = carboplatin.